Translocator Protein (TSPO) Expression in Platelets of Depressed Patients Decreases during Antidepressant Therapy

N. Sarubin; T. C. Baghai; J. M. Lima-Ojeda; D. Melchner; H. Hallof-Buestrich; L. Wolf; S. Hilbert; V. M. Milenkovic; C. H. Wetzel; R. Rupprecht; C. Nothdurfter

doi:10.1055/s-0042-107795

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2016; 49(05): 204-209
DOI: 10.1055/s-0042-107795

Original Paper

Translocator Protein (TSPO) Expression in Platelets of Depressed Patients Decreases during Antidepressant Therapy

N. Sarubin

¹Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

²Hochschule Fresenius, University of Applied Sciences, Munich, Germany

³Department of Psychology, Psychological Methods and Assessment, Ludwig-Maximilians-Universität, Munich, Germany

,

T. C. Baghai

¹Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

,

J. M. Lima-Ojeda

¹Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

,

D. Melchner

¹Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

,

H. Hallof-Buestrich

¹Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

,

L. Wolf

¹Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

,

S. Hilbert

³Department of Psychology, Psychological Methods and Assessment, Ludwig-Maximilians-Universität, Munich, Germany

,

V. M. Milenkovic

¹Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

,

C. H. Wetzel

¹Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

,

R. Rupprecht

¹Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

,

C. Nothdurfter

¹Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

› Institutsangaben

Abstract

Introduction: A promising candidate in the field of pharmacological treatment options regarding major depressive disorder (MDD) is the mitochondrial translocator protein (18 kDa) (TSPO). TSPO is crucial for neurosteroid synthesis, which is in turn important for the regulation of emotions. It has already been shown that TSPO expression in platelets of depressed patients is reduced compared to healthy subjects.

Methods: We measured TSPO levels in platelets of 37 depressed patients before and after 6 weeks of pharmacological treatment to test the hypotheses that i) such treatment would increase TSPO expression and ii) that this increase would be correlated with therapeutic response.

Results: Surprisingly, TSPO levels in platelets of all patients were significantly reduced after 6 weeks of treatment (p=0.044). Within the responder group, a non-significant trend towards greater TSPO level reduction could be observed.

Discussion: These results challenge our hypotheses that TSPO levels might increase during antidepressant therapy along with a decrease in depressive symptoms. Thus, we assume that TSPO expression in platelets is not a suitable state marker for MDD.

Key words

TSPO - platelets - depression - antidepressant - therapy response

Volltext

Referenzen

References
1 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006; 3: e442
2 Gadermann AM, Alonso J, Vilagut G et al. Comorbidity and disease burden in the National Comorbidity Survey Replication (NCS-R). Depress Anxiety 2012; 29: 797-806
3 Rupprecht R, Papadopoulos V, Rammes G et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010; 9: 971-988
4 Gut P, Zweckstetter M, Banati RB. Lost in translocation: the functions of the 18-kD translocator protein. Trends Endocrinol Metab 2015; 26: 349-356
5 Rone MB, Midzak AS, Issop L et al. Identification of a dynamic mitochondrial protein complex driving cholesterol import, trafficking, and metabolism to steroid hormones. Mol Endocrinol 2012; 26: 1868-1882
6 Nguyen N, Fakra E, Pradel V et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 2006; 21: 139-149
7 Schüle C, Nothdurfter C, Rupprecht R. The role of allopregnanolone in depression and anxiety. Prog Neurobiol 2014; 113: 79-87
8 Papadopoulos V, Baraldi M, Guilarte TR et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-409
9 Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int 2002; 40: 475-486
10 Maeda J, Higuchi M, Inaji M et al. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res 2007; 1157: 100-111
11 Chelli B, Pini S, Abelli M et al. Platelet 18 kDa translocator protein density is reduced in depressed patients with adult separation anxiety. Eur Neuropsychopharmacol 2008; 18: 249-254
12 Abelli M, Chelli B, Costa B et al. Reductions in platelet 18-kDa translocator protein density are associated with adult separation anxiety in patients with bipolar disorder. Neuropsychobiology 2010; 62: 98-103
13 Hamilton M. A rating scale for depression. Journal Neurol Neurosurg Psychiatry 1960; 23: 56-62
14 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994
15 Wittchen HU, Wunderlich U, Zaudig M et al. Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. Göttingen: Hogrefe; 1997. Interviewheft
16 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
17 Gilmer 1 WS, Gollan JK, Wisniewski SR et al. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. J Clin Psychiatry 2008; 69: 1246-1256
18 Nussbaumer B, Morgan LC, Reichenpfader U et al. Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis. CNS Drugs 2014; 28: 699-712
19 Sarubin N, Nothdurfter C, Schmotz C et al. Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression. Psychoneuroendocrinology 2014; 39: 141-151
20 Riedel 1 M, Möller HJ, Obermeier M et al. Response and remission criteria in major depression – a validation of current practice. J Psychiatr Res 2010; 44: 1063-1068
21 Weizman A, Burgin R, Harel Y et al. Platelet peripheral-type benzodiazepine receptor in major depression. J Affect Disord 1995; 33: 257-261
22 Setiawan E, Wilson AA, Mizrahi R et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015; 72: 268-275
23 Hannestad J, DellaGioia N, Gallezot JD et al. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [¹¹C]PBR28 PET study. Brain Behav Immun 201 33: 131-138
24 Danovich L, Veenman L, Leschiner S et al. The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. Eur Neuropsychopharmacol 2008; 18: 24-33
25 Dennis T, Beauchemin V, Lavoie N. Antidepressants reverse the olfactory bulbectomy-induced decreases in splenic peripheral-type benzodiazepine receptors in rats. Eur J Pharmacol 1995; 272: 279-288
26 Leschiner S, Weizman R, Shoukrun R et al. Tissue-specific regulation of the peripheral benzodiazepine receptor by antidepressants and lithium. Neuropsychobiology 2000; 42: 127-134
27 Bae KR, Shim HJ, Balu D et al. Translocator protein 18 kDa negatively regulates inflammation in microglia. J Neuroimmune Pharmacol 2014; 9: 424-437
28 Uzunova V, Sheline Y, Davis JM et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998; 95: 3239-3244
29 Costa B, Pini S, Abelli M et al. Role of translocator protein (18 kDa) in adult separation anxiety and attachment style in patients with depression. Curr Mol Med 2012; 12: 483-487
30 Wolf L, Bauer A, Melchner D et al. Enhancing neurosteroid synthesis – relationship to the pharmacology of translocator protein (18 kDa) (TSPO) ligands and benzodiazepines. Pharmacopsychiatry 2015; 48: 72-77